Neratinib, an irreversible pan erB receptor tyrosine kinase inhibitor active for advanced HER2(+ )breast cancer

Gelijkaardige items

• Hyperactivation of TORC1 drives resistance to the pan-HER tyrosine kinase inhibitor neratinib in HER2-mutant cancers
  door: Sudhan, Dhivya R., et al.
  Gepubliceerd in: (2020)
• Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-Mutant Cancers
  door: Sudhan, Dhivya R., et al.
  Gepubliceerd in: (2020)
• Preclinical Characteristics of the Irreversible Pan-HER Kinase Inhibitor Neratinib Compared with Lapatinib: Implications for the Treatment of HER2-Positive and HER2-Mutated Breast Cancer
  door: Collins, Denis M., et al.
  Gepubliceerd in: (2019)
• Phase 1 Studies of Poziotinib, an Irreversible Pan-HER Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors
  door: Kim, Tae Min, et al.
  Gepubliceerd in: (2018)
• HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib
  door: Wang, Y., et al.
  Gepubliceerd in: (2019)